Gamma delta T-cell receptor tumor-associated antigens

Tumor-associated antigens recognized by the γδ T-cell receptor (TCR) comprise a diverse group of molecules that facilitate MHC-independent recognition of malignant cells by unconventional γδ T lymphocytes (Frontiers in Immunology, 2023). Unlike conventional αβ T cells, which require peptide-MHC presentation, γδ T cells identify stress-induced ligands such as phosphoantigens (e.g., IPP), butyrophilin family members (notably BTN3A1 and BTN2A1), and MHC class I-like proteins like MICA and MICB (Science, 2020; NIH, 2021). These antigens are often upregulated in response to metabolic dysregulation or cellular stress, allowing γδ T cells to act as rapid responders in the anti-tumor immune response (Exploration Immunology, 2022). Therapeutic strategies targeting these antigens include aminobisphosphonates that increase endogenous phosphoantigen levels, monoclonal antibodies like ICT01 that stabilize stimulatory butyrophilin conformations, and bispecific Gammabodies that bridge the γδ TCR to tumor-specific markers (Frontiers in Immunology, 2023; NIH, 2020). These approaches aim to exploit the potent cytotoxicity and cytokine production of γδ T cells to treat cancers that are resistant to traditional αβ T-cell-based therapies (Drug Target Review, 2024).

Other names

γδ TCR ligandsGamma delta T-cell receptor antigensPhosphoantigensButyrophilinsStress-induced antigensMHC-independent tumor antigensBTN3A1BTN2A1MICA/B

Modulation of γδ T-cell activity through agonistic stabilization of butyrophilin complexes (e.g., BTN3A1/BTN2A1), metabolic accumulation of endogenous phosphoantigens via FPPS inhibition, or bispecific engagement of the γδ T-cell receptor with tumor-specific surface proteins.